Medicenna Therapeutics Corp (MDNA.TO) is experiencing notable price movements in the market this week.
This week, Medicenna Therapeutics Corp. has seen a rise in its stock price, closing at C$0.38, which marks a 2.63% increase for the day and an 11.43% increase over the week. The company has been active in the capital markets, recently finalizing and closing a public offering that has raised significant funds for its lead programs.
Investor takeaway: Investors should be aware of Medicenna's recent public offering and its implications for the company's financial health and market position, especially given its substantial YTD decline of 61%.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeAdvertisement
Market cap
$34.61M
52W high
$1.97
52W low
$0.34
1W change
+11.43%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 720.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+720.5% Upside
Current Price
C$0.39
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
38.0%
Annualized
90-Day Vol
68.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.37 | C$0.32 – C$0.42 |
| 60 trading days | C$0.35 | C$0.29 – C$0.42 |
| 90 trading days | C$0.33 | C$0.26 – C$0.41 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Medicenna's stock has increased 11.43% this week.
Despite recent gains, the stock remains down 61% year-to-date, highlighting ongoing challenges.
Bull case
The recent public offering raised C$4.44 million, which could provide Medicenna with the necessary capital to advance its clinical programs and potentially lead to future growth.
Bear case
Despite the recent uptick in stock price, Medicenna has faced a significant decline in its stock value year-to-date. The company continues to operate with a negative profit margin and a high beta, indicating volatility.
Recent Price Action
Medicenna Therapeutics Corp. (MDNA.TO) has seen a 2.63% increase in its stock price today, closing at C$0.38. Over the past week, the stock has appreciated by 11.43%. However, it is important to note that the stock has experienced a decline of 1.27% in the last month and a significant drop of 61% year-to-date.
Company News and Catalysts
Advertisement
The recent increase in Medicenna's stock price can be attributed to its successful public offering, which closed on May 28, 2026, raising approximately CDN$4.44 million. This funding is aimed at supporting the company's lead programs. Despite this positive development, there has been no other major news regarding the company this week.
Technical Picture
Medicenna’s stock is currently trading below both its 50-day moving average (C$0.39) and its 200-day moving average (C$0.80), indicating a bearish trend in the long term. The stock has a beta of 1.89, suggesting higher volatility compared to the broader market. The 52-week range for the stock is C$0.34 to C$1.97, with the current price at approximately 2% of this range. Volume has been lower than average, with the latest trading volume at 21,381 shares, compared to a 20-day average of 46,084 shares.
Insider Activity
There is no recent insider activity reported for Medicenna Therapeutics Corp.
Price Action Summary
Medicenna Therapeutics Corp. closed at C$0.38, reflecting a daily increase of 2.63%.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
